Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

2.6K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.6K
Antibody Actions01:26

Antibody Actions

1.3K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

855
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
855
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

810
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
810
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

497
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
497

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individualised treatment effects of corticosteroids in IgA nephropathy.

EBioMedicine·2026
Same author

Response to the Letter to the Editor Entitled "Diagnostic Latency and Unmeasured Disease Severity In Male Lupus Nephritis".

Kidney international reports·2026
Same author

Development and validation of EULAR quality indicators for lupus nephritis: adherence trends and impact on clinical outcomes.

Annals of the rheumatic diseases·2026
Same author

Population pharmacokinetic-based dose adjustment of tiapride in patients with impaired renal function.

Annals of medicine·2026
Same author

Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Beyond fluid overload: uncovering the hidden causes of dyspnea in hemodialysis patients.

Frontiers in medicine·2026

Related Experiment Video

Updated: Sep 3, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.7K

Complement Inhibition in ANCA-Associated Vasculitis.

Vladimir Tesar1, Zdenka Hruskova1

  • 1Department of Nephrology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.

Frontiers in Immunology
|July 26, 2022
PubMed
Summary

Avacopan, a C5a receptor inhibitor, offers effective treatment for ANCA-associated vasculitis (AAV) with fewer corticosteroid-related side effects. This approach targets the alternative complement pathway, improving safety in AAV management.

Keywords:
ANCAANCA - associated vasculitisC5aavacopancomplement

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

7.0K

Related Experiment Videos

Last Updated: Sep 3, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.7K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

7.0K

Area of Science:

  • Immunology
  • Nephrology
  • Rheumatology

Background:

  • Immunosuppressive therapy for ANCA-associated vasculitis (AAV) presents significant toxicity concerns.
  • High-dose corticosteroids, often used with rituximab, are linked to serious adverse events.
  • The alternative complement pathway is implicated in the pathogenesis of AAV.

Purpose of the Study:

  • To evaluate the efficacy and safety of avacopan, a C5a receptor inhibitor, in the induction treatment of AAV.
  • To compare avacopan's safety profile against high-dose corticosteroids regarding corticosteroid-related adverse events.
  • To explore alternative complement pathway inhibition as a therapeutic strategy for AAV.

Main Methods:

  • Clinical trials investigating avacopan for AAV induction therapy.
  • Assessment of treatment efficacy and safety, focusing on corticosteroid-related adverse events.
  • Exploration of complement pathway inhibition mechanisms in AAV.

Main Results:

  • Avacopan demonstrated comparable efficacy to high-dose corticosteroids in AAV induction.
  • Avacopan showed improved safety, specifically reducing corticosteroid-related adverse events.
  • The alternative complement pathway is a viable target for AAV treatment.

Conclusions:

  • Avacopan provides an effective and safer alternative to high-dose corticosteroids for AAV induction.
  • Targeting the alternative complement pathway is a promising strategy for managing AAV.
  • Further research into complement pathway inhibition holds potential for AAV and other glomerular diseases.